

MAURY STRAUSS DISTINGUISHED PUBLIC LECTURE

Presented by the Fralin Biomedical Research Institute at VTC



JOHN C. MORRIS, M.D.

Friedman Distinguished Professor of Neurology
Director, Knight Alzheimer Disease Research Center
Washington University School of Medicine

The New Era in Alzheimer's Diagnosis and Treatment

Since 2023, anti-amyloid immunotherapies have been approved by the United States Food and Drug Administration for the treatment of persons with very mild to mild symptomatic Alzheimer's disease (AD). These amyloid-targeting treatments (ATTs) do not cure AD, but can slow the rate of cognitive and functional decline, thus prolonging the period in which the patient retains independence. However, benefit is optimal when AD is accurately diagnosed early in its symptomatic course. Early diagnosis has now been notably facilitated by the availability of accurate, acceptable, and accessible blood-based biomarker (BBM) tests for AD. Together, BBMs and ATTs usher in a new era in AD diagnosis and treatment.

THURSDAY, MAY 14, at 5:30 p.m.

(Reception and hors d'oeuvres at 5 p.m.)
Room M203, 2 Riverside Circle

Watch via Zoom: <https://FralinBioMed.info/DPL-Join>.



**FRALIN BIOMEDICAL
RESEARCH INSTITUTE AT VTC**
VIRGINIA TECH.